Suppr超能文献

欧盟打击假药 trafficking 的法律方面。(原句中“trafficking”后似乎少了关键内容,比如“trafficking in”之类,导致“假药trafficking”表述不太完整准确)

Legal aspects of counteracting the trafficking of falsified medicines in the european union.

作者信息

Pashkov Vitalii, Soloviov Aleksey, Olefir Andrii

机构信息

Department Of Civil, Economical And Environmental Law Poltava's Institute Of Law Yaroslav Mudryi National Law University, Poltava, Ukraine.

Department Of Management And Economics Of Pharmacy, National Medical Academy Of Postgraduate Education Named P.L.Shupyk, Kyiv, Ukraina.

出版信息

Wiad Lek. 2017;70(4):843-849.

Abstract

INTRODUCTION

The paper identifies key risks associated with the illegal production and sale of medicines. Also there were generalized features of criminal responsibility for acts related to the trafficking of drugs in some Member States of the EU and analyzed legal means of combating the falsified drugs today. The problem concerning falsification of medicines is particularly acute not only in developing countries but also in developed ones. Fake is one in ten - twenty drug. The largest share of falsified drugs comes from the so-called «Asian tigers», already from which they come to the EU market.

THE AIM

In this publication authors have set following objectives: - to determine the risks associated with illegal production and sale of medicines; - organize legal means of combating the falsified medicines in the EU member states; - clarify features of criminal responsibility for acts related to the trafficking of drugs in the EU countries.

MATERIALS AND METHODS

The article bases on the works of scholars and experts, statistical information and other sources. Particular attention is paid to the analysis of regulations of the EU institutions and national criminal laws. So, provisions of the criminal codes of 10 EU member states were taken into account.

RESULTS

There is a system of legal measures which counter the circulation of falsified medicines in the EU and consists of general and specific regulatory requirements, mainly of economic and legal nature. The most important role among the last play package labeling requirements for drugs and license conditions.

DISCUSSION

In the article were discussed factors that stimulate the production and sale of falsified drugs and the risks associated with these. Demarcated the concept of «falsified medicinal product», «counterfeit drug», «substandard drug».

CONCLUSIONS

Although there are guidelines for patients to identify falsified drugs, still a major role in this process should play public authorities and enterprises. In all the countries illegal circulation of falsified drugs is prohibited under threat of criminal or administrative responsibility.

摘要

引言

本文确定了与非法生产和销售药品相关的关键风险。此外,还介绍了欧盟一些成员国对与毒品贩运相关行为的刑事责任的一般特征,并分析了当今打击假药的法律手段。药品造假问题不仅在发展中国家,而且在发达国家都尤为严重。十分之一到二十分之一的药品是假药。最大份额的假药来自所谓的“亚洲四小龙”,它们已经进入了欧盟市场。

目的

在本出版物中,作者设定了以下目标: - 确定与非法生产和销售药品相关的风险; - 在欧盟成员国组织打击假药的法律手段; - 阐明欧盟国家对与毒品贩运相关行为的刑事责任特征。

材料与方法

本文基于学者和专家的著作、统计信息及其他资料来源。特别关注对欧盟机构法规和国家刑法的分析。因此,考虑了10个欧盟成员国刑法典的规定。

结果

欧盟存在一个应对假药流通的法律措施体系,该体系由一般和具体的监管要求组成,主要具有经济和法律性质。其中最重要的是药品包装标签要求和许可条件。

讨论

本文讨论了刺激假药生产和销售的因素以及与之相关的风险。界定了“伪造药品”、“假冒药品”、“不合格药品”的概念。

结论

尽管有指导患者识别假药的指南,但在这一过程中,公共当局和企业仍应发挥主要作用。在所有国家,非法流通假药均被禁止,并会受到刑事或行政责任的威胁。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验